| Serial Number | 79226526 |
| Word Mark | PRIAVOID |
| Filing Date | Tuesday, June 20, 2017 |
| Status | 700 - REGISTERED |
| Status Date | Tuesday, October 16, 2018 |
| Registration Number | 5582971 |
| Registration Date | Tuesday, October 16, 2018 |
| Mark Drawing | 4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form |
| Published for Opposition Date | Tuesday, July 31, 2018 |
| Goods and Services | Pharmaceuticals for the prevention and treatment of allergies and for the abatement of burns; drug delivery agents in the form of capsules that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; pharmaceuticals, namely, anti-infectives, immunostimulants; implantable pharmaceuticals namely, biological tissues grafts; serotherapeutic pharmaceuticals for treatment of meningitis and respiratory disorders; pharmaceutical drugs for treatment of Alzheimer's and dementia; medicated throat sprays; medicine for dental purpose; medicine for veterinary purpose, namely, bacteriostats; medicine for intestinal diseases; pharmaceutical preparations for human purposes, namely, for treatment of Alzheimer's and dementia; pharmaceuticals for the treatment of the autonomic nervous system; pharmaceuticals for the treatment of gastrointestinal diseases; pharmaceutical compounds and products for treatment of Alzheimer's and dementia; chemical and pharmaceutical products and preparations for medical purposes, namely, medical diagnostic reagents; antiepileptic pharmaceutical preparations; pharmaceutical compounds and substances for treatment of Alzheimer's and dementia; chemical compounds for pharmaceutical purpose, namely, for the diagnosis of pregnancy; pharmaceutical agents for metabolism; pharmaceutical agents for treatment of the intestines; pharmaceutical compounds for human use, namely, menstrual symptom treatment preparations; synthetic peptides for pharmaceutical purpose for the prevention and treatment of flu; pharmaceutical agents and compounds for the peripheral nervous system; pharmaceutical products for the treatment of infections; pharmaceutical products for the treatment of hyperlipidemias; crystals for therapeutical purpose being pharmaceutical products, namely, mineral preparations; pharmaceutical compounds for the prevention and treatment of metabolic disorder; pharmaceutical compounds for the treatment of kidney diseases; pharmaceutical compounds for the prevention and treatment of metabolic diseases; chemicals for pharmaceutical use, namely, chemical preparations for the diagnosis of pregnancy; pharmaceutical compounds for the treatment of a chemical imbalance; pharmaceutical preparations for the central nervous system; pharmaceutical compounds for the treatment of diabetes; pharmaceutical compounds for the treatment of Parkinson disease; pharmaceutical compounds for the treatment of multiple sclerosis; pharmaceutical compounds and substances for the prevention of cancer; pharmaceutical compounds and substances with analgesic properties; pharmaceutical compounds for the treatment of epilepsy, disorders of the intestines and of the sensory organs; pharmaceutical compounds for the prevention of disorders and diseases of the nervous system; pharmaceutical compounds and substances for the treatment of cancer and cardiovascular diseases; pharmaceutical compounds and substances for use in oncology; pharmaceutical products and substances for the treatment of gastrointestinal diseases; pharmaceutical compounds for the treatment of diseases of the central nervous system (CNS); biological preparations for treatment of neurological disorders; biological compounds for the treatment of cancer; biochemical compounds for the treatment of cancer and for pain treatment; biotechnological compounds for medical purpose, namely, bioactive pharmaceuticals for treatment of Alzheimer's and dementia; diagnostic biomarker reagents for medical purpose; bio-pharmaceuticals for the treatment of cancer |
| Goods and Services | Chemical substances for the production of pharmaceuticals; esters of fatty acids for use in pharmaceuticals; preservatives for pharmaceutical compounds; antimicrobial preservatives for pharmaceutical compounds; chemicals for the preparation being manufacturing and production of pharmaceuticals; antioxidants for the production of pharmaceutical products; chemical compounds for the preparation being manufacturing of pharmaceutical products; esters being viscose chemicals for the production of pharmaceutical products; preservatives for use in the pharmaceutical industry; softening agents being chemical agents for manufacturing for use during the preparation of pharmaceuticals; chemical products for use in the pharmaceutical industry, namely, for use in pharmaceutical manufacturing; active chemical ingredients for the use during the preparation being manufacturing of pharmaceuticals; biochemical compounds for scientific purposes; biochemical products, namely polypeptides for in vitro research applications; biochemical products, namely, chemical reagents for in vitro genetic technology; reagents for use in scientific apparatus for chemical and biological analysis; diagnostic reagents for in vitro use in biochemistry, clinical chemistry and microbiology; biochemicals, namely, monoclonal antibodies for in vitro scientific or research use |
| Goods and Services | Development of pharmaceutical compounds and drugs; research and development of vaccine and drugs; pharmaceutical product development in relation to drugs; pharmaceutical research, research regarding pharmaceuticals; conducting of quality control tests on pharmaceutical products; medical and pharmaceutical research services; pharmaceutical research and development services; pharmaceutical research and development; development of pharmaceutical products; evaluation of results from quality control tests conducted on goods and services in relation to pharmaceutical products; consulting with regard to pharmacology; laboratory research services with regard to pharmaceuticals; research in the field of pharmaceuticals; consulting with regard to pharmaceutical research and development; scientific research in the field of pharmacy; pharmaceutical product evaluation, namely services for the evaluation of the therapeutic effects of pharmaceuticals; research and development services for the pharmaceutical industry; research and development in the field of pharmacy and biotechnology; information technology (IT) consultancy services for pharmaceutical industry and health sector; quality assessment in the nature of quality testing, analysis and evaluation with regard to research in the field of pharmacogenetics; biochemical research; biological research; biological analysis; biological research services; biological development services; biological laboratory services; biochemical analysis; biomedical research; biotechnological research; research regarding biotechnologies; biotechnological research services; scientific research regarding biology; biological research and analysis; research in the field of biotechnology; consulting in the field of biology; consulting in the field of biochemistry; research and development in the field of biochemistry; research and development services in the field of biotechnology |
| International Class | 001 - Chemicals used in industry, science and photography, as well as in agriculture, horticulture and forestry; unprocessed artificial resins; unprocessed plastics; manures; fire extinguishing compositions; tempering and soldering preparations; chemical substances for preserving foodstuffs; tanning substances; adhesives used in industry. |
| US Class Codes | 001, 005, 006, 010, 026, 046 |
| Class Status Code | 6 - Active |
| Class Status Date | Monday, February 12, 2018 |
| Primary Code | 001 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
| US Class Codes | 006, 018, 044, 046, 051, 052 |
| Class Status Code | 6 - Active |
| Class Status Date | Monday, February 12, 2018 |
| Primary Code | 005 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Monday, February 12, 2018 |
| Primary Code | 042 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| Party Name | Priavoid GmbH |
| Party Type | 30 - Original Registrant |
| Legal Entity Type | 98 - Unknown |
| Address | DE |
| Party Name | Priavoid GmbH |
| Party Type | 20 - Owner at Publication |
| Legal Entity Type | 98 - Unknown |
| Address | DE |
| Party Name | Priavoid GmbH |
| Party Type | 11 - New Owner Before Publication |
| Legal Entity Type | 98 - Unknown |
| Address | DE |
| Party Name | NOT AVAILABLE |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 01 - Individual |
| Address | DE |
| Event Date | Event Description |
| Friday, February 16, 2018 | APPLICATION FILING RECEIPT MAILED |
| Thursday, February 8, 2018 | SN ASSIGNED FOR SECT 66A APPL FROM IB |
| Monday, February 12, 2018 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Monday, February 12, 2018 | ASSIGNED TO EXAMINER |
| Wednesday, February 21, 2018 | NON-FINAL ACTION WRITTEN |
| Thursday, February 22, 2018 | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW |
| Friday, March 2, 2018 | REFUSAL PROCESSED BY MPU |
| Saturday, March 3, 2018 | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB |
| Monday, March 5, 2018 | NON-FINAL ACTION WRITTEN |
| Tuesday, March 6, 2018 | NON-FINAL ACTION MAILED |
| Saturday, March 24, 2018 | REFUSAL PROCESSED BY IB |
| Wednesday, July 11, 2018 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| Wednesday, June 20, 2018 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Wednesday, June 20, 2018 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Thursday, June 21, 2018 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Thursday, June 21, 2018 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Thursday, July 5, 2018 | CHANGE OF OWNER RECEIVED FROM IB |
| Wednesday, July 11, 2018 | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB |
| Tuesday, October 16, 2018 | REGISTERED-PRINCIPAL REGISTER |
| Wednesday, January 16, 2019 | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB |
| Saturday, November 19, 2022 | NEW REPRESENTATIVE AT IB RECEIVED |
| Wednesday, July 11, 2018 | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB |
| Friday, July 27, 2018 | NOTIFICATION PROCESSED BY IB |
| Tuesday, July 31, 2018 | PUBLISHED FOR OPPOSITION |
| Tuesday, July 31, 2018 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| Thursday, January 31, 2019 | FINAL DISPOSITION PROCESSED |
| Thursday, January 31, 2019 | FINAL DISPOSITION NOTICE SENT TO IB |
| Friday, February 22, 2019 | FINAL DECISION TRANSACTION PROCESSED BY IB |
| Saturday, May 11, 2024 | NEW REPRESENTATIVE AT IB RECEIVED |
| Monday, October 16, 2023 | COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED |